{
    "root": "347c906c-7fbd-c0b2-e063-6394a90acb4b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Naltrexone Hydrochloride",
    "value": "20250506",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "68401960MK"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "NALTREXONE HYDROCHLORIDE",
            "code": "Z6375YW9SF"
        }
    ],
    "indications": "Naltrexone hydrochloride tablets USP 50 mg is indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids.\n                  Naltrexone hydrochloride tablets USP 50 mg has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions.",
    "contraindications": "To reduce the risk of precipitated withdrawal in patients dependent on opioids, or exacerbation of a preexisting subclinical withdrawal syndrome, opioid-dependent patients, including those being treated for alcohol dependence, should be opioid-free (including tramadol) before starting naltrexone hydrochloride treatment. An opioid-free interval of a minimum of 7 to 10 days is recommended for patients previously dependent on short-acting opioids.\n                  \n                     Switching from Buprenorphine, Buprenorphine/Naloxone, or Methadone\n                  \n                  There are no systematically collected data that specifically address the switch from buprenorphine or methadone to naltrexone hydrochloride; however, review of postmarketing case reports have indicated that some patients may experience severe manifestations of precipitated withdrawal when being switched from opioid agonist therapy to opioid antagonist therapy (see\n \n  \n                        WARNINGS\n                     ).Patients transitioning from buprenorphine or methadone may be vulnerable to precipitation of withdrawal symptoms for as long as 2 weeks. Healthcare providers should be prepared to manage withdrawal symptomatically with non-opioid medications.",
    "warningsAndPrecautions": "Naltrexone hydrochloride tablets USP 50 mg yellow coloured, oval, biconvex, film-coated tablets with breakline on one side and '50' debossed on the other side. Available in\n                  \n                  NDC: 70518-1146-00\n                  NDC: 70518-1146-01\n                  PACKAGING: 30 in 1 BLISTEER PACK\n                  PACKAGING: 30 in 1 BLISTER PACK \n                  \n                  \n                  Store at 20째 to 25째C (68째 to 77째F). [See USP Controlled Room Temperature].\n                  Dispense in a tight container.\n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Naltrexone hydrochloride is contraindicated in\n                  \n                     Patients receiving opioid analgesics.\n                     Patients currently dependent on opioids, including those currently maintained on opiate agonists (e.g., methadone ) or partial agonists (e.g., buprenorphine)\n                     Patients in acute opioid withdrawal (see\n  \n   \n                           WARNINGS\n                        ).\n \n  \n                     Any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids.\n                     Any individual with a history of sensitivity to naltrexone hydrochloride or any other components of this product.It is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids."
}